Spotlight
Video

KEYNOTE-029 Results: Pembrolizumab + Low-Dose Ipilimumab in Metastatic Melanoma Patients

Loading........
Description: Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC) and advanced melanoma: Phase 1 KEYNOTE-029 study
Shared By : AnnualMeeting2017
Posted on : 06/13/17
Added : 5 months ago



Recommended

Nothing found.

More From AnnualMeeting2017

Nothing found.